Quest Diagnostics Inc (DGX)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Ticker
DGX
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$28.57B
52-week range
$171.18 - $263.19

Valuation

Share price
$259.52 (close of Nov 18, 2026)
P/E (TTM)
25.51x
Price to book
3.59x
Price to free cash flow
20.78x
Enterprise value
$34.05B
Book value per share
$72.27

Price performance

PeriodChange
1 day+1.24%
5 days+0.32%
1 month+10.43%
3 months+9.85%
6 months+36.70%
Year to date+49.55%
1 year+40.04%
3 years+92.39%
5 years+75.56%
10 years+203.39%
All time+7,314.87%

Short interest

As of
Oct 30, 2026
Short % of float
3.41%
Shares short
3.73M
Days to cover
3.64
Change since prior report
+4.48%
Source
FINRA consolidated short interest

Members of Congress who disclosed DGX trades

Julie Johnson · Alan Armstrong · Carol Miller · Julia Letlow

Super investors holding DGX

Christopher Davis (Davis Selected Advisers) · Ken Griffin (Citadel) · Robert Olstein (Olstein Capital Management) · First Eagle Investment (First Eagle Investment Management, LLC) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
13.77%
Return on invested capital
9.01%
Return on assets
6.11%
Return on capital employed
11.16%
Gross margin
33.21%
Net margin
8.99%
EBITDA margin
19.27%
Revenue growth
11.78%
Net income growth
13.89%
Free cash flow growth
49.50%

Cash flow and balance sheet

Free cash flow yield (TTM)
4.81%
Current ratio
1.70x
Net debt to EBITDA
2.34x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$11.04B
Cost of revenue
$7.37B
Gross profit
$3.67B
EBITDA
$2.13B
Net income
$992.00M
Earnings per share
$8.87
Interest expense
$277.00M
Shares outstanding
111.00M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$11.04B$3.67B$992.00M$8.87
2024-12-31$9.87B$3.24B$871.00M$7.78
2023-12-31$9.25B$3.05B$854.00M$7.59
2022-12-31$9.88B$3.43B$946.00M$8.10
2021-12-31$10.79B$4.21B$2.00B$15.85
2020-12-31$9.44B$3.63B$1.43B$10.62
2019-12-31$7.73B$2.69B$858.00M$6.36
2018-12-31$7.53B$2.60B$736.00M$5.39
2017-12-31$7.40B$2.68B$772.00M$5.63
2016-12-31$7.21B$2.90B$645.00M$4.58

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3133.21%8.99%13.77%9.01%
2024-12-3132.86%8.82%12.78%7.72%
2023-12-3133.00%9.23%13.47%8.56%
2022-12-3134.74%9.57%15.95%10.94%
2021-12-3139.02%18.49%30.77%15.97%
2020-12-3138.50%15.16%21.02%13.15%
2019-12-3134.80%11.11%15.09%8.91%
2018-12-3134.59%9.77%13.97%10.03%
2017-12-3136.25%10.43%15.58%10.57%
2016-12-3140.19%8.94%13.84%10.10%

Cash and debt by year

Period endCashDebt
2025-12-31$420.00M$5.17B
2024-12-31$549.00M$5.62B
2023-12-31$686.00M$4.41B
2022-12-31$315.00M$3.98B
2021-12-31$872.00M$4.01B
2020-12-31$1.16B$4.01B
2019-12-31$1.19B$3.97B
2018-12-31$135.00M$3.43B
2017-12-31$137.00M$3.75B
2016-12-31$359.00M$3.73B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.36B$88.00M
2024-12-31$909.00M$88.00M
2023-12-31$864.00M$77.00M
2022-12-31$1.31B$77.00M
2021-12-31$1.83B$79.00M
2020-12-31$1.59B$97.00M
2019-12-31$843.00M$56.00M
2018-12-31$817.00M$61.00M
2017-12-31$923.00M$79.00M
2016-12-31$823.00M$69.00M

Dividend history

Most recent payment
Oct 6, 2026
Paid in the last twelve months
$3.38
Payment dateDividend per share
2026-10-06$0.86
2026-07-08$0.86
2026-04-06$0.86
2026-01-13$0.80
2025-10-03$0.80
2025-07-07$0.80
2025-04-07$0.80
2025-01-14$0.75

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-22Sep 2026$2.85
2026-07-23Jun 2026$2.81
2026-04-21Mar 2026$2.37
2026-02-10Dec 2025$2.36
2025-10-21Sep 2025$2.51
2025-07-22Jun 2025$2.57
2025-04-22Mar 2025$2.15
2025-01-30Dec 2024$2.19

Filings and sources

Company website
questdiagnostics.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Labcorp Holdings Inc. (LH) · Mettler-Toledo International Inc (MTD) · Medpace Holdings, Inc. (MEDP) · Illumina, Inc. (ILMN) · Revvity, Inc. (RVTY) · Waters Corp (WAT) · Charles River Laboratories International, Inc. (CRL) · IDEXX Laboratories Inc (IDXX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades